HK1205948A1 - 阿片樣製劑 - Google Patents

阿片樣製劑

Info

Publication number
HK1205948A1
HK1205948A1 HK15106598.6A HK15106598A HK1205948A1 HK 1205948 A1 HK1205948 A1 HK 1205948A1 HK 15106598 A HK15106598 A HK 15106598A HK 1205948 A1 HK1205948 A1 HK 1205948A1
Authority
HK
Hong Kong
Prior art keywords
opioid formulations
opioid
formulations
Prior art date
Application number
HK15106598.6A
Other languages
English (en)
Inventor
Fredrik Tiberg
Ian Harwigsson
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1205948(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Priority claimed from PCT/EP2013/065855 external-priority patent/WO2014016428A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of HK1205948A1 publication Critical patent/HK1205948A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
HK15106598.6A 2012-07-26 2015-07-10 阿片樣製劑 HK1205948A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28
PCT/EP2013/065855 WO2014016428A1 (en) 2012-07-26 2013-07-26 Opioid formulations

Publications (1)

Publication Number Publication Date
HK1205948A1 true HK1205948A1 (zh) 2015-12-31

Family

ID=53487482

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15106598.6A HK1205948A1 (zh) 2012-07-26 2015-07-10 阿片樣製劑
HK16109379.4A HK1221636A1 (zh) 2012-07-26 2016-08-05 阿片樣物質製劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16109379.4A HK1221636A1 (zh) 2012-07-26 2016-08-05 阿片樣物質製劑

Country Status (20)

Country Link
US (2) US20240075024A1 (zh)
JP (1) JP6417327B2 (zh)
CN (1) CN109010255B (zh)
AU (3) AU2016244271B2 (zh)
CL (1) CL2015000197A1 (zh)
CY (1) CY1124016T1 (zh)
DK (1) DK2877155T3 (zh)
EA (1) EA034855B1 (zh)
ES (1) ES2837803T3 (zh)
HK (2) HK1205948A1 (zh)
HR (1) HRP20210068T1 (zh)
HU (1) HUE053273T2 (zh)
IL (3) IL296882A (zh)
LT (1) LT2877155T (zh)
MX (1) MX361873B (zh)
MY (1) MY189481A (zh)
NZ (2) NZ735248A (zh)
PE (1) PE20150672A1 (zh)
PT (1) PT2877155T (zh)
SG (2) SG10201703964TA (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
AU2018345844B2 (en) * 2017-10-06 2024-03-07 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
CN117999079A (zh) * 2021-08-20 2024-05-07 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP5127449B2 (ja) * 2004-06-04 2013-01-23 カムルス エービー 流体デポ製剤
WO2006075123A1 (en) * 2005-01-14 2006-07-20 Camurus Ab Topical bioadhesive formulations
SI1845942T1 (sl) * 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
PE20150672A1 (es) 2015-05-21
MX361873B (es) 2018-12-18
IL289157A (en) 2022-02-01
MY189481A (en) 2022-02-16
PT2877155T (pt) 2020-12-18
SG11201500554XA (en) 2015-02-27
US20240075024A1 (en) 2024-03-07
AU2017279657B2 (en) 2018-11-15
HUE053273T2 (hu) 2021-06-28
AU2016244271A1 (en) 2016-10-27
EA034855B1 (ru) 2020-03-30
CN109010255A (zh) 2018-12-18
SG10201703964TA (en) 2017-06-29
JP2015522649A (ja) 2015-08-06
US20240226091A9 (en) 2024-07-11
IL296882A (en) 2022-12-01
EA201590202A1 (ru) 2015-07-30
HRP20210068T1 (hr) 2021-03-05
HK1221636A1 (zh) 2017-06-09
JP6417327B2 (ja) 2018-11-07
AU2019200982A1 (en) 2019-02-28
MX2015001033A (es) 2015-04-09
US20240131021A1 (en) 2024-04-25
BR112015001548A2 (pt) 2017-07-04
CN109010255B (zh) 2022-10-21
ES2837803T3 (es) 2021-07-01
NZ735248A (en) 2018-10-26
AU2016244271B2 (en) 2018-01-18
AU2017279657A1 (en) 2018-01-18
CY1124016T1 (el) 2022-05-27
DK2877155T3 (da) 2021-01-18
LT2877155T (lt) 2021-02-25
AU2019200982B2 (en) 2019-07-18
NZ704012A (en) 2017-09-29
CL2015000197A1 (es) 2015-11-13
IL236762A0 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
GB201304182D0 (en) No details
GB201403961D0 (en) No details
PL2877155T3 (pl) Formulacje opioidowe
GB201411220D0 (en) No details
HK1202445A1 (zh) 新製劑
IL289157A (en) Opioid compounds
HK1205679A1 (zh) 尼古丁製劑
PT2908835T (pt) Formulações estáveis
GB201313844D0 (en) No details
PL2908859T3 (pl) Formulacje arypiprazolu
GB201403415D0 (en) No details
GB201110278D0 (en) Formulations
IL234771B (en) Nicotine formulation
GB201206178D0 (en) Formulations
GB201211247D0 (en) Improved formulation
GB201322955D0 (en) No details
GB201400108D0 (en) No details
GB201302155D0 (en) No details
GB201300109D0 (en) No details
GB201310646D0 (en) No details
GB201220529D0 (en) No details available
GB201107627D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations